Denali Therapeutics has finalized U.S. launch readiness for tividenofusp alfa (DNL310) in Hunter syndrome ahead of an April 5,...

Pacira BioSciences posted 2025 revenue of $726 million, up 4% year over year, with a record fourth quarter for...

Biodesix reported a breakout quarter to close 2025, delivering $28.8 million in Q4 revenue with 83% gross margins and,...

mdxhealth posted fourth-quarter revenue of $29.5 million, up 19% year over year, and full-year 2025 revenue of $107.9 million,...

Aztiq Pharma Partners has consolidated its stake in Alvotech through an internal transfer of 2,701,617 shares at USD 4.74...

Ligand Pharmaceuticals reported a decisive acceleration in its royalty-driven model, with full-year 2025 royalty revenue up 48% to $161...

Rhythm Pharmaceuticals reported fourth-quarter 2025 net product revenue of $57.3 million and set a near-term regulatory catalyst: a March...

Indivior posted record quarterly and full-year performance anchored by Sublocade, its long-acting buprenorphine injection for opioid use disorder. Total...

C4 Therapeutics has dosed the first patient in MOMENTUM, a Phase 2 study of the IKZF1/3 molecular glue degrader...

Kymera Therapeutics closed 2025 with two Phase 2b trials underway for KT-621, its first-in-class oral STAT6 degrader, in atopic...